Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease

F. Cox, R. Trincher, J. P. Rissing, M. Patton, G. H. McCracken, D. M. Granoff

Research output: Contribution to journalArticlepeer-review


Rifampin prophylaxis (20 mg/kg once daily for four days) was used in close contacts of children with Haemophilus influenzae type b (HIB) disease. Two hours after a dose, the concentration of rifampin in serum and saliva exceeded the minimum bactericidal concentrations of organisms obtained from four of the carriers. In both a randomized prospective and an open study, nasopharyngeal carriage was eradicated in 37 (95%) of 39 contacts. No cases of serious H influenzae disease occurred in four to six months of follow-up. At the dose and treatment schedule used, rifampin was safe and effective for eradication of HIB carriage.

Original languageEnglish (US)
Pages (from-to)1043-1045
Number of pages3
JournalJournal of the American Medical Association
Issue number10
StatePublished - May 8 1981

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Rifampin prophylaxis for contacts of Haemophilus influenzae type b disease'. Together they form a unique fingerprint.

Cite this